Reduced Duration of Postchikungunya Musculoskeletal Pain in Rheumatological Patients Treated with Biologicals

Table 2

Duration of CHIK symptoms comparing patients with positive IgG using biological DMARDs with the controls and comparing anti-TNF biologicals with other bDMARDs.

Symptom duration	bDMARD N (%)	Control N (%)	Total	value (ARR; 95% CI)
<3 months	23 (72%)	5 (36%)	28	0.021 (−0.362; −0.457 to −0.266)
>3 months	9 (28%)	9 (64%)	18
	Anti-TNF	Control
<3 months	19 (95%)	5 (36%)	24	0.001 (−0.593; −0.748 to −0.437)
>3 months	1 (5%)	9 (64%)	10
	Other bDMARD	Control
<3 months	4 (33%)	5 (36%)	9	0.899 (0.024; 0.040 to 0.008)
>3 months	8 (67%)	9 (64%)	17

bDMARD: biological disease-modifying antirheumatic drug; ARR: absolute risk reduction; other bDMARD included abatacept, rituximab, tocilizumab, and secukinumab.